OverviewSuggest Edit

BioSpecifics Technologies is a biopharmaceutical company which engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company offers injectable collagenase in Canada and Australia, as well as in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The Company is also involved in the development of other clinical indications for which collagenase injection has been tested.

TypePublic
Founded1957
HQLynbrook, US
Websitebiospecifics.com

Latest Updates

Employees (est.) (Dec 2019)7(+40%)
Revenue (FY, 2019)$38.2 M(+16%)
Share Price (Sept 2020)$53.7
Cybersecurity ratingAMore

Key People/Management at BioSpecifics Technologies

Joseph Truitt

Joseph Truitt

Chief Executive Officer & Director
Mike Sherman

Mike Sherman

Director & Audit Committee Financial Expert
Alex Monteith

Alex Monteith

Chief Business Officer
Patrick Hutchison

Patrick Hutchison

Chief Financial Officer
Show more

BioSpecifics Technologies Office Locations

BioSpecifics Technologies has offices in Lynbrook and Wilmington
Lynbrook, US (HQ)
35 Wilbur St
Wilmington, US
2 Righter Pkwy #200
Show all (2)

BioSpecifics Technologies Financials and Metrics

BioSpecifics Technologies Revenue

BioSpecifics Technologies's revenue was reported to be $38.19 m in FY, 2019
USD

Revenue (Q2, 2020)

3.9m

Net income (Q2, 2020)

115.8k

EBIT (Q2, 2020)

(250.9k)

Market capitalization (22-Sept-2020)

394.4m

Closing stock price (22-Sept-2020)

53.7

Cash (30-Jun-2020)

16.9m

EV

377.7m
BioSpecifics Technologies's current market capitalization is $394.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

11.4m11.1m14.5m14.1m22.8m26.3m27.4m33.0m38.2m

Revenue growth, %

15%

General and administrative expense

5.2m4.8m5.0m5.8m7.3m7.9m8.5m8.8m9.3m

R&D expense

972.1k1.2m1.5m1.3m1.0m1.3m1.2m756.8k590.3k
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

BioSpecifics Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

BioSpecifics Technologies Online and Social Media Presence

Embed Graph

BioSpecifics Technologies News and Updates

BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development

LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...

BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results

LYNBROOK, N.Y., Nov. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...

BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids

LYNBROOK, N.Y., Oct. 31, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...

BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results

LYNBROOK, N.Y., Aug. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in...

BioSpecifics Technologies Blogs

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results

- Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019 -
Show more

BioSpecifics Technologies Frequently Asked Questions

  • When was BioSpecifics Technologies founded?

    BioSpecifics Technologies was founded in 1957.

  • Who are BioSpecifics Technologies key executives?

    BioSpecifics Technologies's key executives are Joseph Truitt, Mike Sherman and Alex Monteith.

  • How many employees does BioSpecifics Technologies have?

    BioSpecifics Technologies has 7 employees.

  • What is BioSpecifics Technologies revenue?

    Latest BioSpecifics Technologies annual revenue is $38.2 m.

  • What is BioSpecifics Technologies revenue per employee?

    Latest BioSpecifics Technologies revenue per employee is $5.5 m.

  • Who are BioSpecifics Technologies competitors?

    Competitors of BioSpecifics Technologies include ViewPoint Therapeutics, Nordic Nanovector and Y-mAbs Therapeutics.

  • Where is BioSpecifics Technologies headquarters?

    BioSpecifics Technologies headquarters is located at 35 Wilbur St, Lynbrook.

  • Where are BioSpecifics Technologies offices?

    BioSpecifics Technologies has offices in Lynbrook and Wilmington.

  • How many offices does BioSpecifics Technologies have?

    BioSpecifics Technologies has 2 offices.